# Ketamine Treatment for PTSD and MDD in TBI

> **NCT06228391** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Minneapolis Veterans Affairs Medical Center** · enrollment: 40 (estimated)

## Conditions studied

- PTSD, Post Traumatic Stress Disorder
- Major Depressive Disorder
- Traumatic Brain Injury

## Interventions

- **DRUG:** IV ketamine
- **DRUG:** Midazolam

## Key facts

- **NCT ID:** NCT06228391
- **Lead sponsor:** Minneapolis Veterans Affairs Medical Center
- **Sponsor class:** FED
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-03
- **Primary completion:** 2026-12
- **Final completion:** 2027-03
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2024-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06228391

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06228391, "Ketamine Treatment for PTSD and MDD in TBI". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06228391. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*